Literature DB >> 10829268

Fluoroquinolones.

J A O'Donnell1, S P Gelone.   

Abstract

The fluoroquinolone class of antimicrobial agents has expanded dramatically in the last 5 years and will continue to grow over the next decade. This article discusses the newer fluoroquinolones in detail, including pharmacokinetics, pharmacodynamics, safety, and drug interactions, and the spectrum of in vitro activity. Newer agents are compared and contrasted with the older ones, particularly ciprofloxacin and ofloxacin, and problems with liver toxicity and trovafloxacin are described. Finally, appropriate use of the fluoroquinolones is discussed, including their role in the treatment of urinary tract infections, sexually transmitted diseases, gastrointestinal infections, osteomyelitis, and respiratory tract infections.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10829268     DOI: 10.1016/s0891-5520(05)70260-9

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  13 in total

1.  Comparative pharmacodynamics of three newer fluoroquinolones versus six strains of staphylococci in an in vitro model under aerobic and anaerobic conditions.

Authors:  David H Wright; Brent W Gunderson; Laurie B Hovde; Gigi H Ross; Khalid H Ibrahim; John C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

Review 2.  Antibiotics and breast-feeding: a critical review of the literature.

Authors:  Allison M Chung; Michael D Reed; Jeffrey L Blumer
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 3.  Selective drug delivery to bone using acidic oligopeptides.

Authors:  Junko Ishizaki; Yoshihiro Waki; Tatsuo Takahashi-Nishioka; Koichi Yokogawa; Ken-Ichi Miyamoto
Journal:  J Bone Miner Metab       Date:  2008-11-19       Impact factor: 2.626

4.  Quinolone Resistance: Older Concepts and Newer Developments.

Authors:  Darrin J. Bast; Joyce C. S. de Azavedo
Journal:  Curr Infect Dis Rep       Date:  2001-02       Impact factor: 3.725

5.  Bone-targeting of quinolones conjugated with an acidic oligopeptide.

Authors:  Tatsuo Takahashi; Koichi Yokogawa; Naoki Sakura; Masaaki Nomura; Shinjiro Kobayashi; Ken-ichi Miyamoto
Journal:  Pharm Res       Date:  2008-07-29       Impact factor: 4.200

6.  A seizure attributed to ofloxacine in a woman undergoing detoxification for alcohol dependence.

Authors:  Pierre Lahmek; Laurent Michel; Nadine Meunier; Henri-Jean Aubin
Journal:  Case Rep Med       Date:  2010-01-24

7.  Value of preapproval safety data in predicting postapproval hepatic safety and assessing the legitimacy of class warning.

Authors:  Yeong-Liang Lin; Ya-Chi Wu; Churn-Shiouh Gau; Min-Shung Lin
Journal:  Ther Adv Drug Saf       Date:  2012-02

8.  In vitro activities of 25 quinolones and fluoroquinolones against liver and blood stage Plasmodium spp.

Authors:  Nassira Mahmoudi; Liliane Ciceron; Jean-François Franetich; Khemais Farhati; Olivier Silvie; Wijnand Eling; Robert Sauerwein; Martin Danis; Dominique Mazier; Francis Derouin
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

9.  Chronic administration of caderofloxacin, a new fluoroquinolone, increases hepatic CYP2E1 expression and activity in rats.

Authors:  Li Liu; Ming-xing Miao; Ze-yu Zhong; Ping Xu; Yang Chen; Xiao-dong Liu
Journal:  Acta Pharmacol Sin       Date:  2016-02-01       Impact factor: 6.150

Review 10.  Fluoroquinolone-induced liver injury: three new cases and a review of the literature.

Authors:  Anna Licata; Claudia Randazzo; Ilaria Morreale; Giuseppe Butera; Natale D'Alessandro; Antonio Craxì
Journal:  Eur J Clin Pharmacol       Date:  2012-01-14       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.